E-Cadherin Expression on Urothelial Carcinoma and Its Association with Cancer Progression: A Retrospective Study
Keywords:
Bladder Cancer, E-Cadherin, Metastasis, Recurrence, SurvivalAbstract
Background: Bladder cancer is characterized by high recurrence and progressivity. E-cadherin serves as one of the most important molecules involved in the epithelial cells cell to cell adherence, suggested to inhibit tumor cells progression. This study aims to investigate the association between the E-cadherin expression with bladder cancer progressiveness in three years. Methods: This study was a retrospective cohort study involving bladder cancer patients. Diagnosis of bladder cancer was confirmed by histopathological and immunohistochemical examination with both grading and staging determined by histopathologist and oncologists. E- cadherin was examined through immunohistochemistry examination at the time of diagnosis. Data on demography, muscle invasion, clinical staging, grade, metastasis, multifocality and recurrence were obtained from medical records and pathology reports. The association of E-cadherin expression to muscle invasion and non-muscle invasion bladder cancer was evaluated and statistically analyzed. Patients’ survival data were followed up by phone. Results: Forty bladder cancer patients with a mean age of 60.05 +/_ 10.3 years were included. Most subjects had high E- cadherin expression (85%), muscle invasion (65%), high grade (65%), no metastasis (87.5%), multifocality (65%) and no recurrence (62.5%). Lower expression of E- cadherin was associated with the higher clinical stage (p<0.02) and metastasis(p<0.001). Patients with low E-cadherin expression showed worse cumulative survival than the higher one (mean 32 months vs 25 months, p= 0.13). Conclusion: Low level of E-cadherin was associated with the higher risk of muscle invasion, clinical staging, histological grade and risk of metastasis. Meanwhile, patients with high level of E- cadherin showed a better 3-year survival rate.
References
1. Zhao X, Qi X, Liu D, Che X, Wu G. A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System. Int J Nanomedicine. 2024 Dec 17;19:13461-13483. doi: 10.2147/IJN.S498729. PMID: 39713223; PMCID: PMC11662911.
2. Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol Metab (Seoul). 2022 Oct;37(5):703-718. doi: 10.3803/EnM.2022.1553. PMID: 36193717; PMCID: PMC9633223.
3. Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023 Jun;136:123-143. doi: 10.1016/j.humpath.2022.08.006. PMID: 36084769.
4. Cheng S, Li C, Liu L, Liu X, Li M, Zhuo J, Wang J, Zheng W, Wang Z. Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma. Biol Direct. 2024 Mar 7;19(1):20. doi: 10.1186/s13062-023-00446-x. PMID: 38454507; PMCID: PMC10918934.
5. Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells. 2019 Sep 20;8(10):1118. doi: 10.3390/cells8101118. PMID: 31547193; PMCID: PMC6830116.
6. Corso G, Figueiredo J, De Angelis SP, Corso F, Girardi A, Pereira J, Seruca R, Bonanni B, Carneiro P, Pravettoni G, Guerini Rocco E, Veronesi P, Montagna G, Sacchini V, Gandini S. E-cadherin deregulation in breast cancer. J Cell Mol Med. 2020 Jun;24(11):5930-5936. doi: 10.1111/jcmm.15140. PMID: 32301282; PMCID: PMC7294130.
7. Balamurugan K, Poria DK, Sehareen SW, Krishnamurthy S, Tang W, McKennett L, Padmanaban V, Czarra K, Ewald AJ, Ueno NT, Ambs S, Sharan S, Sterneck E. Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 Mar 22;8(6):e156057. doi: 10.1172/jci.insight.156057. PMID: 36757813; PMCID: PMC10070121.
8. Singh M, Sahay R, Tiwari K, Prakash S. Relevance of the Immunohistochemical Expression of p53 and E-cadherin in the Grading of Urothelial Carcinoma: A Single-Center Cross-Sectional Observational Study. Cureus. 2024 Oct 22;16(10):e72132. doi: 10.7759/cureus.72132. PMID: 39575056; PMCID: PMC11581451.
9. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.
10. Edechi CA, Amini M, Hamedani MK, Terceiro LEL, Nickel BE, Leygue E, Myal Y. Comparison of Fixation Methods for the Detection of Claudin 1 and E-Cadherin in Breast Cancer Cell Lines by Immunofluorescence. J Histochem Cytochem. 2022 Feb;70(2):181-187. doi: 10.1369/00221554211055240. PMID: 34715746; PMCID: PMC8777374.
11. Martins-Lima C, Miranda-Gonçalves V, Lobo J, Constâncio V, Leite-Silva P, Guimarães-Teixeira C, Monteiro-Reis S, Sequeira JP, Cantante M, Gonçalves CS, Costa BM, Henrique R, Jerónimo C. Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. Cell Oncol (Dordr). 2022 Feb;45(1):135-149. doi: 10.1007/s13402-021-00657-2. PMID: 35064910.
12. Ying Y, Wang Z, Tan Y, Cao H, Gao H, Zhang Z, Zeng S, Xu C. Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer. Transl Androl Urol. 2023 Feb 28;12(2):176-186. doi: 10.21037/tau-22-538. PMID: 36915888; PMCID: PMC10006009.
13. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. PMID: 34511303.
14. Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec;42(34):4095-4102. doi: 10.1200/JCO.23.02510. PMID: 39226514; PMCID: PMC11960038.
15. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Erratum in: Eur Urol. 2020 Jul;78(1):e48-e50. doi: 10.1016/j.eururo.2020.03.017. PMID: 31753752.
16. Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Sæbjørnsen S, Veskimäe E, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Erratum in: Eur Urol. 2024 Jun;85(6):e180. doi: 10.1016/j.eururo.2024.03.002. PMID: 37858453.
17. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29. PMID: 32360052.
18. Zhao Y, Lu SM, Zhong B, Wang GC, Jia RP, Wang Q, Long JH. Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients. Medicine (Baltimore). 2024 Apr 26;103(17):e37934. doi: 10.1097/MD.0000000000037934. PMID: 38669432; PMCID: PMC11049731.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Joy Prokas Biswas, Bijoy Prokas Biswas, Tirtha Khastagir, Tasnova Tabassum, Gobinda Chowdhury, Faima Amin Liza, Jahidul Kabir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
